Penn's leading scientists in CAR-T and mRNA, Carl June and Drew Weissman, are among the company's founders.

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as ...

Cash resources totaled approximately $225 million as of June 30, 2025CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its ...

As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by ...